Director of Inserm Research Centre U897, “Epidemiology and Biostatistics Center”
+33 5 57 57 16 59
Benzodiazepines and psychotropic drugs are the mostly widely used drugs in France. It is estimated that 30% of people aged 65 and over are users. They are prescribed for a wide spectrum of illnesses, from sleep disorders through to anxiety and depressive symptoms. Since they are widely used, the researchers are looking at their potential side-effects in relation to their interactions with neurotransmitters in the brain. Although previous studies had already suggested an increased risk of dementia following use of psychotropic drugs, many questions remained unresolved. One such question concerned the difference in the potential effects of short half-life benzodiazepines (which disappear from the body within 20 hours) versus those of long half-life benzodiazepines.
To try to find out more, the Inserm researchers focused on data from The Three City Study (3C Study; Bordeaux, Dijon and Montpellier), i.e. 8,240 people aged over 65 years and monitored for over 8 years. 830 new cases of dementia were diagnosed during this period of monitoring. A procedure for screening and diagnosing each case of dementia was established by an expert committee. It was also possible to systematically record all drugs used by the participants at home, by referring to prescriptions.
“There is a clear difference in effect between long- and short-lived benzodiazepines. Moreover, the former have already been identified as dangerous for older people, particularly because of the risk of falls, and we were surprised to see that they were still in frequent use,” says Christophe Tzourio, neurologist, Director of Inserm Research Centre U897 and Professor of Epidemiology at the University of Bordeaux.
Older people taking long half-life benzodiazepines have a 60% increased risk of developing a dementia (mainly of Alzheimer’s disease type) that cannot be explained by other factors. The authors performed in-depth statistical analyses that allowed the elimination of some bias, including the fact that taking benzodiazepines may have been due to early symptoms of dementia.
It is, however, an observational study, which does not allow analysis of the mechanisms of this association. These should become the subject of physiopathological studies, studies using imaging, animal models, etc.
Despite the absence of certainty about the mechanism, “The suspicion is strong enough to encourage physicians and patients to find alternative treatments for sleep disorders in older patients, which are the main reason for prescribing these drugs: advice on lifestyle changes, non-drug products, and, at most, less dangerous drugs such as the short half-life benzodiazepines.”
“Our results suggest, at a minimum, that there should be greater vigilance by all, especially physicians and health authorities, to avoid this use of long half-life benzodiazepines in older people,” says Christophe Tzourio.
The effect for psychotropic drugs overall, including anti-depressants, needs to be confirmed by further studies, but it also gives rise to some concerns over these products as a whole, and not only benzodiazepines.
An international research team involving Inserm and the National Institutes of Health (NIH) has just published the results of the PREVAIL study on treatment for the Ebola virus. While not definitive, the results show that ZMapp may benefit patients with the Ebola ...
JUMODA, a prospective study sponsored by the Paris public hospitals (AP-HP) and conducted between 2014 and 2015 by teams of researchers and clinicians from Inserm, Université Paris Descartes and AP-HP, has shed new light on the mode of delivering twins. According to ...
Benzodiazepine, psychotropic medication, and dementia: a population-based cohort study
Dalia Shash*, MSc; Tobias Kurth*, MD, ScD; Marion Bertrand, MSc, Carole Dufouil, PhD; Pascale Barberger-Gateau, MD, PhD; Claudine Berr, MD, PhD, Karen Ritchie, MD, PhD; Jean-Francois Dartigues, MD, PhD, Bernard Bégaud, MD, PhD, Annick Alpérovitch, MD, PhD; Christophe Tzourio, MD, PhD
* These authors contributed equally to the work.
From Inserm Research Center for Epidemiology and Biostatistics (U897) – Team Neuroepidemiology (DS, TK, MB, AA, CT), F-33000 Bordeaux, France
University of Bordeaux (DS, TK, CD, PBG, BB, CT), F-33000 Bordeaux France,
Inserm Unit 897—Epidemiology and Biostatistics Research Center (U897) – Team epidemiology and neuropsychology of cerebral aging (CD, PBG, JFD), F-33000 Bordeaux, France
Inserm Unit 1061—Neuropsychiatry (CB, KR): epidemiological and clinical research, F-34000, Montpellier, France
University of Montpellier, F-34000 Montpellier, France
Inserm Unit 657— Pharmacoepidemiology and Evaluation of the Impact of Health Products on Populations (BB), F-33000 Bordeaux, France